Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Echinacea not effective in treating colds in children

03.12.2003


Echinacea is not effective in shortening the duration or decreasing the severity of upper respiratory tract infections in children, according to a study in the December 3 issue of The Journal of the American Medical Association (JAMA).



Upper respiratory tract infections (URIs) are a significant health burden in childhood, according to background information in the article. The average child has six to eight colds each year, each lasting seven to nine days. While children are frequently given drugs such as decongestants, antihistamines, and cough suppressants to reduce symptoms, there is little evidence that these medications are effective in children younger than 12 years. The authors add that it has been estimated that 11 percent to 21 percent of children in the United States and Canada who are receiving care from conventional physicians are also using alternative therapies. Echinacea, one of the most commonly used herbal remedies in the U.S., has been used extensively for the prevention and treatment of URIs in adults.

James A. Taylor, M.D., from the University of Washington, Seattle, and colleagues, conducted a randomized controlled trial to determine the effectiveness and safety of Echinacea purpurea (a type of echinacea used for medicinal purposes) in treating URIs in children two to 11 years old. A total of 524 children were included in the study. The patients were randomized to receive either echinacea or placebo for up to three URIs over a four-month period. The echinacea or placebo was started at the onset of symptoms and continued for a maximum of ten days.


Data were analyzed on 707 URIs that occurred in 407 children, including 337 who were treated with echinacea and 370 with placebo. There were 79 children who completed the study period without getting a URI. The median (half were more; half were less) duration of the URIs was 9 days.

"There was no difference in duration between upper respiratory tract infections treated with echinacea or placebo," the authors report. "There was also no difference in the overall estimate of severity of upper respiratory tract infection symptoms between the two treatment groups (median, 33 in both groups). In addition, there were no statistically significant differences between the two groups for peak severity of symptoms, number of days of peak symptoms (1.60 in the echinacea group and 1.64 in the placebo group), number of days of fever (0.81 in the echinacea group vs. 0.64 in the placebo group), or parental global assessment of severity of the upper respiratory tract infection." The authors note there was no difference in the rate of adverse events (unwanted side effects) reported in the two treatment groups. However, rashes occurred during 7.1 percent of the upper respiratory tract infections treated with echinacea and 2.7 percent of those treated with placebo.

"Given its lack of documented efficacy and an increased risk for the development of rash, our results do not support the use of echinacea for treatment of URIs (upper respiratory tract infections) in children 2 to 11 years old. Further studies using different echinacea formulations, doses, and dosing frequencies are needed to delineate any possible role for this herb in treating colds in young patients," the authors conclude.

Jennifer Seymour | EurekAlert!
Further information:
http://www.ama-assn.org/
http://jama.com

More articles from Studies and Analyses:

nachricht Smart Data Transformation – Surfing the Big Wave
02.12.2016 | Fraunhofer-Institut für Angewandte Informationstechnik FIT

nachricht Climate change could outpace EPA Lake Champlain protections
18.11.2016 | University of Vermont

All articles from Studies and Analyses >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Significantly more productivity in USP lasers

In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.

Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...

Im Focus: Shape matters when light meets atom

Mapping the interaction of a single atom with a single photon may inform design of quantum devices

Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

Closing the carbon loop

08.12.2016 | Life Sciences

Applicability of dynamic facilitation theory to binary hard disk systems

08.12.2016 | Physics and Astronomy

Scientists track chemical and structural evolution of catalytic nanoparticles in 3-D

08.12.2016 | Materials Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>